Nasdaq
$1.45▲ 0.69%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $12.0MShares out 8.2M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
28- 5d agoPre-market26.10.20 20:468-KKey event#●●●
Lipocine Inc.
Lipocine Inc. has released an updated corporate presentation to be used in meetings with investors and analysts. The presentation is available as Exhibit 99.1 in the company's 8-K filing.…more
$1.45+0.69%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.7Pre-market26.10.07 19:108-KKey event
Lipocine Inc.
Lipocine Inc. announced that its licensing partner, Verity Pharmaceuticals, has received approval from Health Canada for TLANDO, an oral testosterone replacement therapy. Verity Pharmaceuticals plans to launch and commercialize the product in the Canadian market by the end of 2026.…more
$1.45+0.69%vs prev closeView filingShare - 10.2Overnight26.10.02 09:284Ownership
Lipocine Inc.
Lipocine Inc. insider John W. Higuchi filed a Form 4 on October 1, 2026, reporting a change in beneficial ownership of securities as of September 29, 2026.…more
$1.45+0.69%vs prev closeView filingShare
27 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.7Regular26.10.07 23:44#●●●#●●●
Lipocine's Oral Testosterone Therapy TLANDO Receives Health Canada Approval…more
Lipocine's oral testosterone replacement therapy, TLANDO, has received regulatory approval from Health Canada. Licensing partner Verity Pharmaceuticals plans to launch the product in the Canadian market by the end of 2026.…more
$1.45+0.69%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 10.7Pre-market26.10.07 19:25
●●●●●●●● ●●●●● ●●●●●●
Lipocine's licensing partner, Verity Pharmaceuticals, has received approval from Health Canada for TLANDO capsules to treat testosterone deficiency in adult males. Verity Pharma plans to launch and commercialize the product in the Canadian market by the end of 2026.…more
$1.45+0.69%vs prev closeShareBenzinga - 9.14Pre-market26.09.14 21:06
●●●●●●●● ●●●●● ●●●●●●
Lipocine announced the initiation of a Phase 3 study for its oral postpartum depression treatment, LPCN 1154. The trial will enroll approximately 120 participants, with the first dosing expected in early Q4 2026.…more
$1.45+0.69%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report